Then come the multiple brands in Novos incretin franchise, namely the injectables Ozempic and Wegovy, along with experimental agent CagriSema and oral drug Rybelsus
To view a copy of this licence, visit About this article Cite this article Suter, B., Rhodes, A., Bigeh, A
Setting expectations at 1522% over 1218 months is both achievable and clinically meaningful for most people starting at therapeutic doses
*Correspondence: Tina Vilsbll [email protected] This article was submitted to Cellular Endocrinology, a section of the journal Frontiers in Endocrinology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Consider the delivery vehicle: Both are injectable, but peptides (MOTS-C) can sometimes be more sensitive to the pH of the reconstitution water than small molecules (1MQ)